Medicines Optimisation
MMS® can provide tailored medicines optimisation programmes that support clinicians to provide improved healthcare for their patients. We can work alongside you to provide improved patient outcomes as well as offer significant savings for you and the NHS.
Our range of therapy optimisation programmes can be delivered with flexible models in both delivery and funding. These can include part or full sponsorship, in which case clinical reviews may be implemented with no cost implications to your GP Practice, CCG or Federation.
We can implement a fully trained clinical pharmacist to work with patients face to face or manage your medicines optimisation remotely. Our pharmacist can highlight changes that may need to be made and work to provide a solution that is clinically appropriate as well as cost effective.
QIPP Initiatives
MMS® can provide a series of Therapy Optimisation Programmes that can maximise QIPP potential. These programmes are designed to optimise patient care whist releasing budgetary savings in line with national QIPP challenges.
Our range of therapy optimisation programmes can be offered with flexible models in both delivery and funding. These include part or full sponsorship, in which case clinical reviews may be implemented with no cost implications to your GP Practice, CCG or GP Federation.
An ‘invest to save’ model including options for risk share would typically deliver in excess of a five-fold return on investment. On average our suite of optimisation programmes generate a deliverable saving projection of £500,000 per 100,000 population.
Our programmes are highly customisable and can be tailored to suit your requirements. Please contact MMS® for further information and to speak to a member of our senior clinical team.
Medicines Optimisation Programmes
Popular MMS® Programmes
MMS® have designed over 20 programmes to support NHS QIPP and medicines optimisation priorities
across a broad range of therapy areas & conditions.
Key features & benefits include;
-
Optimise therapeutic management of patients
-
Promote alignment to national & local guidance
-
Maximise opportunities to reduce cost and medicines waste
-
Reduce medicines related adverse effects and admissions
Case Example: Model 1 QIPP Programme
MMS® Worked in collaboration with commissioning groups and pharma industry to meet challenges and provide significant outcomes across a CCG in the North East of England.
Commissioning for quality
MMS® can provide skilled clinical pharmacists to undertake patient centred clinical review projects to improve patient health outcomes in line with CCG objectives and NHS Right Care strategies.
MMS® have experience in delivering in the following areas:
- Care Home Reviews
- Stroke Prevention
- Domiciliary and Frailty Reviews
- Reducing risk of hospital admission / Virtual Clinics
- Embedding GP Practice Pharmacists
Please contact MMS for more information on our Medicines Optimisation Programmes or to speak to one of our Senior Clinical Team
MMS Frail & Elderly Prescribing reviews – Maximising Quality Prescribing
Polypharmacy within the frail & elderly is an emerging problem and is associated with increased risks:
- Patients on 10 or more medicines are over 3 times more likely to be admitted to hospital
- Between 30-50% of prescribed medicines are not taken as recommended
- Adverse Drug Reactions (ADRs) account for 6.5% of hospital admissions, of which 70% are avoidable
- At least 6% of emergency admissions are caused by medicines
Department of Health & Social Care research has estimated that primary care medication errors leading to hospital admissions cause 627 deaths and cost the NHS £83.7m a year. in total across the NHS it is estimated that medication errors caused 712 deaths a year, costing £98.5m.
MMS have developed service models to support NHS organisations to review the most vulnerable and improve outcomes for the frail and care home populations.
